Jetrea Solution For Injection 2.5Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

JETREA: Solution for injection (2.5mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

OCRIPLASMIN is an injectable medicine for the eye. It is used to treat vitreomacular adhesion with symptoms.

In-Depth Information

JETREA 2.5 mg/mL Solution for Injection

NDC: 248560001
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Vitreomacular Adhesion

Storage Information
Reconstituted product should be used immediately. Discard unused portion
Store in original package until time of use
Protect from light
Store frozen product at or below -4 degrees F
JETREA 2.5 mg/mL Solution for Injection

Reported Side Effects for JETREA 2.5 mg/mL Solution for Injection

Eye Irritation Incidence:
<5.0%*
Severity: MILD
Onset: RAPID
Macular Edema Incidence:
<5.0%*
Severity: SEVERE
Onset: DELAYED
Cataracts Incidence:
<5.0%*
Severity: MODERATE
Onset: DELAYED
Dry Eyes Incidence:
<5.0%*
Severity: MILD
Onset: EARLY
Light Sensitivity Incidence:
<5.0%*
Severity: MODERATE
Onset: EARLY
Inflamed Iris (Eye) Incidence:
<5.0%*
Severity: MODERATE
Onset: DELAYED
Red Eyes Incidence:
<5.0%*
Severity: MODERATE
Onset: EARLY
Retinal Detachment Incidence:
0.9%*
Severity: SEVERE
Onset: DELAYED
Color Blindness Incidence:
2.0%*
Severity: MODERATE
Onset: DELAYED
Bleeding Within The Eye Incidence:
2.4%*
Severity: SEVERE
Onset: DELAYED
High Eye Blood Pressure Incidence:
4.1%*
Severity: SEVERE
Onset: DELAYED
Eye Pain Incidence:
5.0-20.0%*
Severity: MILD
Onset: EARLY
Blurred Vision Incidence:
5.0-20.0%*
Severity: MODERATE
Onset: EARLY
Photopsia Incidence:
5.0-20.0%*
Severity: MODERATE
Onset: DELAYED
Retinal Edema Incidence:
5.0-20.0%*
Severity: SEVERE
Onset: DELAYED
Visual Impairment Incidence:
5.6%*
Severity: SEVERE
Onset: EARLY
Eye Inflammation Incidence:
7.1%*
Severity: MODERATE
Onset: EARLY
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

SECOND Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

THIRD Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

Lactation

Caution - Not enough information is available to rule out harm to infants when this drug is taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with JETREA

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5